Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2021 Earnings Conference Call February 11, 2021 4:30 PM ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - President and Chief Executive Officer Judy Murrah - Chief Operating Officer Conference Call Participants Yi Chen - H.C. Wainwright Jonathan Aschoff - ROTH Capital Partners Jon Salmanson - Hubble Wealth Management Operator Good afternoon and welcome to the Applied DNA Sciences’ Fiscal First Quarter ...

Financial Data and Key Metrics Changes - Total revenues for Q4 fiscal 2020 declined to $314,000 from $1.7 million in the prior period, primarily due to a decrease in product revenue from the textile industry [8][11] - Product revenues fell to $123,000 for Q4 fiscal 2020, down from $1.3 million in the prior period, while service revenue decreased to $191,000 from $423,000 [8][11] - Net loss widened to $4.1 million in Q4 fiscal 2020 compared to $1.2 million in the same period last year, with adjusted EBITDA at negative $3.8 million [11][12] - Cash and cash equivalents totaled $7.8 million as of September 30, 2020, with an average monthly cash burn rate of $980,000, an increase of 111% year-over-year [11][12] Business Line Data and Key Metrics Changes - The tagging and related supply chain services business experienced a decline in revenue due to the pandemic's impact on global supply chains, particularly in the textile industry [6][7] - Investments were made in COVID-19 testing products and services, which did not significantly contribute to Q4 revenues as contracts were signed late in the quarter [7][8] - Operating expenses increased by 31% to $4.2 million, driven by higher SG&A and R&D expenditures [9][10] Market Data and Key Metrics Changes - The company has established a diversified customer base for its safeCircle platform, including schools, businesses, and hospitals, with over 30 customers currently [46][47] - The Suffolk County government awarded a contract valued at up to $2 million for pooled surveillance testing, which could expand based on demand [16][30] Company Strategy and Development Direction - The company is pivoting towards COVID-19 diagnostics and therapeutics, with a focus on developing its LinearDNA platform for vaccines and diagnostics [19][32] - Plans to commercialize the LinearDNA platform for veterinary use are underway, with trials set to launch in March [21][22] - The safeCircle platform is designed for pooled surveillance testing, which can be adapted for various respiratory viruses beyond COVID-19 [40][41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong commitments from employees, investors, and partners despite the challenges posed by the pandemic [71] - The company anticipates that the revenues from the safeCircle surveillance business will exceed the growth rate expected from its traditional tagging business [47] Other Important Information - The company has maintained ongoing contracts in its tagging business and has obtained several issued patents that strengthen its position in the market [42] - The company is now debt-free, having repaid its secured convertible notes, with the exception of a Paycheck Protection Program loan [12][13] Q&A Session Summary Question: What role does CLEARED4 play in the Suffolk County Government contract? - CLEARED4 provides a flexible platform for tracking information and communication, and the company pays a fee for their service [44][45] Question: How many customers are on the safeCircle platform and will current revenue compensate for lost textile revenue? - The customer base includes over 30 diversified clients, and the revenue from safeCircle is expected to exceed the growth rate of the tagging business [46][47] Question: Is the cat vaccine trial on track and what about the human vaccine? - The cat vaccine trial is expected to proceed as planned, and insights gained may inform the development of the human vaccine [48][49] Question: Can you elaborate on the write-off for development expenses related to the cannabis industry? - The company is shifting its tagging methods to be more relevant to the cannabis supply chain, focusing on tagging during the chemical processing stages [61][62] Question: What were the deficiencies in the CLIA certification and when will they be addressed? - Most concerns were related to data flow in electronic systems, which have been addressed, and documentation is being submitted to the New York State Department of Health [66][67] Question: Any additional insights on gross margin and SG&A expenses for fiscal '21? - SG&A levels are expected to decrease slightly, while gross margins are anticipated to improve with the growth of the surveillance testing business [68][69]

PART I [Business](index=6&type=section&id=ITEM%201.%20BUSINESS) Applied DNA Sciences leverages its PCR-based LinearDNA platform for biotherapeutic manufacturing, supply chain security, and COVID-19 diagnostics, focusing on biopharma and COVID-19 revenue growth [Overview and Business Segments](index=6&type=section&id=Overview%20and%20Business%20Segments) The LinearDNA platform drives biotherapeutics, COVID-19 diagnostics, surveillance, iCTC technology, and non-biologic tagging for supply chain security - The company's proprietary PCR-based LinearDNA platform is central to its operations, enabling large-scale DNA production for biotherapeutics, diagnostics, and supply chain security[18](index=18&type=chunk) - In response to the pandemic, the company developed and received FDA Emergency Use Authorization (EUA) for its Linea™ COVID-19 Assay Kit in May 2020 and launched the safeCircle™ pooled surveillance testing service[18](index=18&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - The company is also developing an invasive circulating tumor cell (iCTC) technology for cancer diagnostics and continues its Non-Biologic Tagging business for anti-counterfeiting[18](index=18&type=chunk)[31](index=31&type=chunk)[32](index=32&type=chunk) [Strategy](index=9&type=section&id=Strategy) Strategy targets growth in COVID-19 diagnostics and biopharma services via the DNA platform, complemented by strategic acquisitions and alliances - The company expects future revenue growth to be driven by sales of its Linea™ COVID-19 Assay Kit, COVID-19 Surveillance Testing, and DNA manufacturing for the biotech and diagnostic markets[41](index=41&type=chunk) - A key part of the strategy is to pursue strategic acquisitions and collaborations to strengthen core technologies and enter new markets[42](index=42&type=chunk) [Markets and Competition](index=10&type=section&id=Markets%20and%20Competition) The company competes in DNA diagnostics, biotherapeutics, and anti-counterfeit tagging, facing established players in each market - The company competes in the DNA Diagnostics market, which is projected to reach **$23.8 billion by 2022**[44](index=44&type=chunk) - The company has a multi-year supply agreement with FUJIFILM Wako Pure Chemical Corp. for bulk DNA used in in vitro medical diagnostics[45](index=45&type=chunk) - Key competitors in the nucleic-acid based therapeutic and DNA manufacturing markets include Aldevron, LLC, Integrated DNA Technologies, Inc., and Novartis AG[82](index=82&type=chunk) - Competitors in the anti-counterfeiting market include Authentix, Inc., De La Rue Plc., and Oritain Global Limited[84](index=84&type=chunk) [Research and Development](index=16&type=section&id=Research%20and%20Development) R&D targets linear DNA biotherapeutics, COVID-19 diagnostics, and DNA tagging, with expenses rising in fiscal 2020 R&D Expense | Fiscal Year | R&D Expense (Approx.) | | :--- | :--- | | 2020 | $3.3 million | | 2019 | $3.0 million | - R&D efforts include developing linear DNA-based COVID-19 and cancer vaccine candidates in collaboration with Takis/Evvivax[71](index=71&type=chunk) [Customer Concentration](index=18&type=section&id=Customer%20Concentration) Significant customer concentration, with a few customers driving substantial revenue and accounts receivable, presents a material business risk Customer Concentration | Metric | Fiscal Year 2020 | Fiscal Year 2019 | | :--- | :--- | :--- | | **Revenue Concentration** | **46% from 4 customers** | **68% from 3 customers** | | **Accounts Receivable Concentration** | **74% from 4 customers** | **77% from 1 customer** | [Government Regulation](index=20&type=section&id=Government%20Regulation) Products, particularly diagnostics and biopharma, face extensive government regulation, including temporary FDA EUA for COVID-19 tests and potential LDT oversight - The Linea™ COVID-19 Assay Kit operates under an FDA Emergency Use Authorization (EUA), which is effective only for the duration of the public health emergency and can be revoked[92](index=92&type=chunk)[115](index=115&type=chunk) - Surveillance testing is not regulated by the FDA, and CLIA certification is not required to conduct it, according to current CMS guidance[93](index=93&type=chunk) - The company's iCTC capture assay is currently considered a Laboratory Developed Test (LDT), a category over which the FDA is exercising enforcement discretion, and future regulation could impose significant costs and delays[111](index=111&type=chunk)[220](index=220&type=chunk) [Risk Factors](index=29&type=section&id=ITEM%201A.%20RISK%20FACTORS) Significant risks include going concern doubts, potential EUA revocation, COVID-19 test obsolescence, customer concentration, intense competition, and regulatory hurdles - The company's financial condition, including a history of net losses, raises **substantial doubt about its ability to continue as a going concern**[132](index=132&type=chunk)[149](index=149&type=chunk) - The Linea™ COVID-19 Assay Kit is sold under an FDA EUA that could be revoked or terminated, and the COVID-19 Surveillance Testing could become obsolete, particularly with the rollout of vaccines[135](index=135&type=chunk)[136](index=136&type=chunk)[167](index=167&type=chunk) - The company's opportunities in pharmaceuticals and biologics require substantial additional funding and face significant development and regulatory risks[134](index=134&type=chunk)[158](index=158&type=chunk) - The company faces intense competition in all its markets, including supply chain security, diagnostics, and biotherapeutics, from larger companies with greater resources[137](index=137&type=chunk)[138](index=138&type=chunk)[182](index=182&type=chunk) [Unresolved Staff Comments](index=50&type=section&id=ITEM%201B.%20UNRESOLVED%20STAFF%20COMMENTS) The company reports no unresolved staff comments from the SEC - None[252](index=252&type=chunk) [Properties](index=50&type=section&id=ITEM%202.%20PROPERTIES) Headquarters and primary labs are in a leased 30,000 sq ft facility in Stony Brook, NY, with a satellite testing facility in Ahmedabad, India - The company's headquarters is a **30,000 sq. ft. leased facility** in Stony Brook, NY, with the lease renewed until January 2022[253](index=253&type=chunk) - A satellite testing facility is maintained in Ahmedabad, India, with a lease renewed until September 2021[253](index=253&type=chunk) [Legal Proceedings](index=51&type=section&id=ITEM%203.%20LEGAL%20PROCEEDINGS) The company is not currently involved in any material legal proceedings that would adversely affect its business or financial condition - The company is not currently involved in any material legal proceedings[254](index=254&type=chunk) [Mine Safety Disclosures](index=51&type=section&id=ITEM%204.%20MINE%20SAFETY%20DISCLOSURES) This item is not applicable to the company - Not applicable[255](index=255&type=chunk) PART II [Market for Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=52&type=section&id=ITEM%205.%20MARKET%20FOR%20COMMON%20EQUITY,%20RELATED%20STOCKHOLDER%20MATTERS%20AND%20ISSUER%20PURCHASES%20OF%20EQUITY%20SECURITIES) The company's common stock trades on Nasdaq under "APDN", with no history or anticipation of cash dividend payments - The company's common stock trades on **The Nasdaq Capital Market** under the symbol "APDN"[257](index=257&type=chunk) - No cash dividends have ever been paid, and none are anticipated in the foreseeable future[259](index=259&type=chunk) [Selected Financial Data](index=52&type=section&id=ITEM%206.%20SELECTED%20FINANCIAL%20DATA) As a Smaller Reporting Company, this information is not applicable due to scaled disclosure requirements - Not applicable as the company is a Smaller Reporting Company[260](index=260&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=52&type=section&id=ITEM%207.%20MANAGEMENT'S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) FY2020 revenue fell 64% to $1.9 million, net loss increased 51% to $13.0 million, raising going concern doubts despite $19.4 million in financing [Results of Operations](index=55&type=section&id=Results%20of%20Operations) FY2020 total revenues fell 64.2% to $1.9 million, product and service revenues declined, R&D rose 12%, resulting in a $13.0 million net loss Financial Performance Summary | Financial Metric | FY 2020 | FY 2019 | Change (%) | | :--- | :--- | :--- | :--- | | **Total Revenues** | **$1,931,497** | **$5,389,089** | **(64.2%)** | | Product Revenues | $615,430 | $2,136,055 | (71.2%) | | Service Revenues | $1,316,067 | $3,253,034 | (59.6%) | | **Cost of Revenues** | **$720,900** | **$877,613** | **(17.9%)** | | **Operating Expenses** | **$13,745,596** | **$13,635,747** | **0.8%** | | R&D Expenses | $3,321,763 | $2,967,278 | 12.0% | | SG&A Expenses | $10,138,103 | $10,278,045 | (1.4%) | | **Net Loss** | **($13,028,904)** | **($8,632,446)** | **51.0%** | - The decrease in product revenue was primarily driven by a **$1.35 million decline** in textiles-related shipments of DNA concentrate, attributed to the global shutdown from the COVID-19 pandemic[283](index=283&type=chunk) - The increase in R&D expense was mainly due to costs associated with the development and validation of the Linea™ COVID-19 Assay Kit and COVID-19 Surveillance Testing[287](index=287&type=chunk) [Liquidity and Capital Resources](index=58&type=section&id=Liquidity%20and%20Capital%20Resources) As of Sep 30, 2020, cash was $7.8 million and working capital $4.8 million; recurring losses raise going concern doubts, despite $19.4 million in financing - The company has recurring net losses and an accumulated deficit of **$269.8 million** as of September 30, 2020, raising **substantial doubt about its ability to continue as a going concern**[297](index=297&type=chunk)[385](index=385&type=chunk) Liquidity Metrics | Metric | As of Sep 30, 2020 | | :--- | :--- | | Cash and cash equivalents | **$7,786,743** | | Working capital | **$4,811,847** | | Cash used in operations (FY2020) | **($11,143,059)** | | Cash from financing (FY2020) | **$19,434,512** | - In November 2019, the company closed an underwritten public offering, raising approximately **$10.8 million in net proceeds**[301](index=301&type=chunk)[302](index=302&type=chunk) - Subsequent to year-end, in October 2020, the company received **$1.67 million** from a warrant exercise and repaid **$1.67 million** in secured convertible notes[321](index=321&type=chunk)[327](index=327&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=65&type=section&id=ITEM%207A.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) As a Smaller Reporting Company, this information is not applicable due to scaled disclosure requirements - Not applicable as the company is a Smaller Reporting Company[331](index=331&type=chunk) [Financial Statements and Supplementary Data](index=65&type=section&id=ITEM%208.%20FINANCIAL%20STATEMENTS%20AND%20SUPPLEMENTARY%20DATA) This section refers to the consolidated financial statements and the independent auditor's report, included from page F-1 to F-30 - The company's audited consolidated financial statements for the fiscal years ended September 30, 2020 and 2019 are included in the report[331](index=331&type=chunk) [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=65&type=section&id=ITEM%209.%20CHANGES%20IN%20AND%20DISAGREEMENTS%20WITH%20ACCOUNTANTS%20ON%20ACCOUNTING%20AND%20FINANCIAL%20DISCLOSURE) This item is not applicable to the company - Not applicable[331](index=331&type=chunk) [Controls and Procedures](index=66&type=section&id=ITEM%209A.%20CONTROLS%20AND%20PROCEDURES) As of September 30, 2020, management concluded that disclosure controls and procedures and internal control over financial reporting were effective - Management concluded that the company's disclosure controls and procedures were effective as of September 30, 2020[334](index=334&type=chunk) - Management's assessment concluded that internal control over financial reporting was effective as of September 30, 2020[336](index=336&type=chunk) [Other Information](index=66&type=section&id=ITEM%209B.%20OTHER%20INFORMATION) The company reports no other information for this item - None[337](index=337&type=chunk) PART III [Directors, Executive Officers, Corporate Governance, Compensation, Security Ownership, and Accountant Fees](index=67&type=section&id=ITEMS%2010-14) Information for Items 10-14, including directors, executive compensation, and accountant fees, is incorporated by reference from the 2021 proxy statement - Information for Items 10, 11, 12, 13, and 14 is incorporated by reference from the company's definitive proxy statement to be filed within 120 days of the fiscal year-end[339](index=339&type=chunk) PART IV [Exhibits and Financial Statement Schedules](index=67&type=section&id=ITEM%2015.%20EXHIBITS%20AND%20FINANCIAL%20STATEMENT%20SCHEDULES) This section lists documents filed as part of Form 10-K, including consolidated financial statements and exhibits, with schedules omitted as not applicable - The consolidated financial statements for the years ended September 30, 2020 and 2019, along with the independent auditor's report, are filed with this report[340](index=340&type=chunk) - An index of all exhibits filed with the report is provided[341](index=341&type=chunk)

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q3 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sanjay Hurry - Executive Director of Investor Relations & Corporate Communications Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President & Chief Executive Officer Conference Call Participants Yi Chen - H.C. Wainwright Anthony Vendetti - Maxim Operator Good day, and welcome to the Applied DNA Sciences Fiscal Third Quarter 2020 Financial Results Conference Call. All par ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value APDN The Nasdaq Capital Market FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q2 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Judy Murrah - Chief Information Officer James Hayward - Chairman, President and CEO Beth Jantzen - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Yi Chen - H.C. Wainwright Craig Pierce - Morgan Stanley Paul Cooney - Joseph Gunnar Operator Good day, and welcome to the Applied DNA Sciences Fiscal Second Quarter 2020 Conference Call. All participants will be in l ...

PART I - FINANCIAL INFORMATION [Item 1 - Condensed Consolidated Financial Statements (unaudited)](index=4&type=section&id=Item%201%20-%20Condensed%20Consolidated%20Financial%20Statements%20(unaudited)) Unaudited financials show increased assets, decreased revenues, a net loss, and key subsequent events Condensed Consolidated Balance Sheet Highlights (unaudited) | Balance Sheet Item | March 31, 2020 (USD) | September 30, 2019 (USD) | | :--- | :--- | :--- | | Cash and cash equivalents | $8,662,889 | $558,988 | | Total current assets | $9,979,073 | $2,146,308 | | Total Assets | $11,326,897 | $3,564,735 | | Total current liabilities | $1,849,884 | $2,245,990 | | Total liabilities | $4,058,121 | $4,413,234 | | Total equity (deficit) | $7,268,776 | ($848,499) | Condensed Consolidated Statements of Operations Highlights (unaudited) | Metric | Three Months Ended Mar 31, 2020 (USD) | Three Months Ended Mar 31, 2019 (USD) | Six Months Ended Mar 31, 2020 (USD) | Six Months Ended Mar 31, 2019 (USD) | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $552,473 | $778,468 | $1,185,992 | $1,662,791 | | Loss from operations | ($2,682,208) | ($2,632,637) | ($5,293,626) | ($5,828,795) | | Net loss | ($2,950,905) | ($2,686,757) | ($5,613,646) | ($5,921,077) | | Net loss per share (basic and diluted) | ($0.79) | ($3.22) | ($1.76) | ($6.51) | Condensed Consolidated Statements of Cash Flows Highlights (unaudited) | Cash Flow Activity (Six Months Ended) | March 31, 2020 (USD) | March 31, 2019 (USD) | | :--- | :--- | :--- | | Net cash used in operating activities | ($5,151,404) | ($3,802,025) | | Net cash used in investing activities | ($44,752) | ($63,986) | | Net cash provided by financing activities | $13,300,059 | $3,747,588 | | Net increase (decrease) in cash | $8,103,903 | ($118,423) | - Subsequent to quarter end, the company received a **$0.85 million** loan under the Paycheck Protection Program (PPP) on May 1, 2020[84](index=84&type=chunk) - The company received Emergency Use Authorization (EUA) from the U.S. FDA for its Linea COVID-19 diagnostic assay kit on **May 13, 2020**[88](index=88&type=chunk) [Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202%20-%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses revenue changes, funding activities, and the uncertain impact of COVID-19 on operations Revenue Comparison (Three Months Ended March 31) | Revenue Type | 2020 (USD) | 2019 (USD) | Change (%) | | :--- | :--- | :--- | :--- | | Product revenues | $197,801 | $119,036 | +66% | | Service revenues | $354,672 | $659,432 | -46% | Revenue Comparison (Six Months Ended March 31) | Revenue Type | 2020 (USD) | 2019 (USD) | Change (%) | | :--- | :--- | :--- | :--- | | Product revenues | $435,671 | $440,747 | -1% | | Service revenues | $750,321 | $1,222,044 | -39% | - A public offering on **November 15, 2019**, raised **$10.5 million** in net proceeds, supplemented by **$2.77 million** and **$2.91 million** from subsequent warrant exercises[141](index=141&type=chunk) - Management projects sufficient cash and cash equivalents to fund operations for the **next twelve months** from the report's filing date[142](index=142&type=chunk) - The COVID-19 pandemic has caused a decline in non-biological tagging revenues, with the overall future impact on operations and liquidity remaining **uncertain**[144](index=144&type=chunk)[145](index=145&type=chunk) [Item 3 - Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203%20-%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is not required to provide market risk disclosures - As a **smaller reporting company**, Applied DNA Sciences, Inc. is exempt from providing quantitative and qualitative market risk disclosures[147](index=147&type=chunk) [Item 4 - Controls and Procedures](index=39&type=section&id=Item%204%20-%20Controls%20and%20Procedures) Disclosure controls were effective as of March 31, 2020, with no material changes to internal controls - The CEO and CFO concluded that disclosure controls and procedures were **effective** as of **March 31, 2020**[149](index=149&type=chunk) - No material changes to internal control over financial reporting occurred during the quarter ended **March 31, 2020**[150](index=150&type=chunk) PART II - OTHER INFORMATION [Item 1 – Legal Proceedings](index=40&type=section&id=Item%201%20%E2%80%93%20Legal%20Proceedings) The company reported no legal proceedings during the period - No legal proceedings were reported[152](index=152&type=chunk) [Item 1A – Risk Factors](index=40&type=section&id=Item%201A%20%E2%80%93%20Risk%20Factors) A new risk factor addresses the potential material adverse impact of the COVID-19 pandemic on the company - A new risk factor addresses the potential **material adverse impact** of the COVID-19 global pandemic on the company's business[153](index=153&type=chunk) - Revenues from non-biological tagging and related services have already **declined** due to COVID-19[154](index=154&type=chunk) [Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds](index=40&type=section&id=Item%202%20%E2%80%93%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or use of proceeds were reported for the period - No unregistered sales of equity securities were reported[155](index=155&type=chunk) [Item 3 – Defaults Upon Senior Securities](index=40&type=section&id=Item%203%20%E2%80%93%20Defaults%20Upon%20Senior%20Securities) The company reported no defaults upon senior securities - No defaults upon senior securities were reported[155](index=155&type=chunk) [Item 4 – Mine Safety Disclosures](index=40&type=section&id=Item%204%20%E2%80%93%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Mine safety disclosures are **not applicable**[155](index=155&type=chunk) [Item 5 – Other Information](index=40&type=section&id=Item%205%20%E2%80%93%20Other%20Information) The company reported no other information - No other information was reported[155](index=155&type=chunk) [Item 6 – Exhibits](index=40&type=section&id=Item%206%20%E2%80%93%20Exhibits) This section lists exhibits filed with the Form 10-Q, including certifications and XBRL data files - This section lists all exhibits filed with the quarterly report, including **officer certifications** and **XBRL interactive data files**[156](index=156&type=chunk)